Bioceres Crop Solutions Corp.

Good morning. Welcome to today's BioSales Crop Solutions fiscal fourth quarter and full year 2024 financial results conference call. My name is Nandija and I will be your moderator for today's call. All lines will be muted during the presentation with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the conference over to our host, Paola Savanti, Head of Investor Relations. Please go ahead.

Thank you, and good morning. Thank you to everyone for joining our fourth quarter and fiscal year 2024 earnings call. Our presentation today will be led by our chief executive officer, Federico Trucco, and our chief financial officer, Enrique Lopez Lecube. Both of them will be available for the Q&A session following the presentation. Before we proceed, I would like to make the following safe harbor statement. Today's call will contain forward-looking statements. And I refer you to the forward-looking statement section of the earnings release and presentation, as well as the recent filings with the SEC. We assume no obligation to update or revise any forward-looking statements to reflect new or changed circumstances. This conference call is being webcast, and the webcast link is available at the Bioceres Crop Solutions Investor Relations website. I will now turn over the call to our CEO, Federico Trucco, to begin our presentation today. Thank you.

Thanks, Paula, and good morning to everyone. Please turn to slide number three to review the highlights for today's presentation. Fiscal year 2024 has been another challenging year for agriculture, with on-farm economics declining in key crops and geographies, particularly in the second half of the fiscal period. For instance, the price of soybeans, a key crop in our portfolio, has dropped by 28% since January, just to provide one metric that strongly correlates with the purchasing power of our end users. Despite this general situation, we were able to consolidate Biocetis' financial performance at record high revenue and EBITDA levels at 464.8 million, and 81.4 million, respectively. We closed the year with improved momentum in the last quarter, which we already anticipated during our third quarter call. We grew sales by 18% in the quarter and almost doubled our EBITDA for the period, with almost half of this improvement resulting from HB4 sales. as Enrique and I will discuss further in the subsequent sections of this presentation. Although the improvement in the quarter fell short of what we needed to meet our annual growth expectations, and as a company we cannot be satisfied with less than double-digit growth, and we certainly expect it to do better, we need to recall that last year's performance was outstanding. with 25% and 31% improvements in our revenue and EBITDA metrics, respectively, at a time when performance in our industry was on a significant decline. Finally, we'll discuss the recent release for HP4Weed in the United States, as well as reorganizational changes regarding key leadership positions in the United States and Brazil. which we believe will help us accelerate growth in these key markets. Before that, I will now pass the presentation over to Enrique for a more detailed discussion of our numbers.